Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Thoracic Disease|April 12, 2021
High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinomaTakamasa Hotta, Kazuhisa Nakashima, Kojiro Hata, et al.
Cancers|June 19, 2024
Real-World Prevalence and Tolerability of Immune-Related Adverse Events in Older Adults with Non-Small Cell Lung Cancer: A Multi-Institutional Retrospective StudyRyosuke Matsukane, Takahiro Oyama, Ryosuke Tatsuta, et al.
Respiratory Medicine Case Reports|December 24, 2025
Lung adenocarcinoma with EGFR exon 19 insertion identified using a compact panel and its response to osimertinib: a case reportMika Horie, Kazuhisa Nakashima, Kojiro Hata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 2020
[Utility of the Filter Extraction Method for Detecting Anticancer Drug Contamination in Air]Toshihiro Irisa, Kojiro Hata, Kazue Nakashima, et al.
Scientific Reports|July 24, 2021
Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapyRyosuke Matsukane, Hiroyuki Watanabe, Kojiro Hata, et al.
International Journal of Clinical Oncology|May 11, 2023
Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomesRyosuke Matsukane, Kimitaka Suetsugu, Kojiro Hata, et al.
Journal for Immunotherapy of Cancer|January 11, 2025
Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitisRyosuke Matsukane, Shoji Nakamura, Haruna Minami, et al.
Biological & Pharmaceutical Bulletin|March 31, 2024
Risk Factors of Cetuximab-Induced Hypomagnesemia and the Effect of Magnesium Prophylaxis in Patients with Head and Neck Cancer: A Retrospective StudyRyosuke Matsukane, Risa Isshiki, Kimitaka Suetsugu, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinomaKojiro Hata, Kimitaka Suetsugu, Nobuaki Egashira, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodiesYasuto Yoneshima, Kentaro Tanaka, Yoshimasa Shiraishi, et al.
Pageof 2